2seventy bio Inc (TSVT) Reports Mixed Financial Results Amid Strategic Shift and Competitive ... [Yahoo! Finance]
2seventy bio, Inc. (TSVT)
Company Research
Source: Yahoo! Finance
Net Loss : Reported a net loss of $56.8 million in Q4 and $217.6 million for the full year, showing an improvement from the previous year's losses. Research and Development : R&D expenses decreased to $51.2 million in Q4, down from $60.1 million in the same period last year. Cash Position : Ended the quarter with $221.8 million in cash and equivalents, with a cash runway extended beyond 2027. Strategic Realignment : Announced a focus on Abecma and an asset sale to Regeneron, expected to close in the first half of 2024, potentially saving $150 million annually. Warning! GuruFocus has detected 3 Warning Signs with TSVT. On March 5, 2024, 2seventy bio Inc ( NASDAQ:TSVT ) released its 8-K filing , detailing the fourth quarter and full year financial results for the period ending December 31, 2023. The company, a cell and gene therapy entity dedicated to cancer treatments, has recently undergone a strategic pivot to focus on its flagship product, Abecma, in collaboration with Br
Show less
Read more
Impact Snapshot
Event Time:
TSVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSVT alerts
High impacting 2seventy bio, Inc. news events
Weekly update
A roundup of the hottest topics
TSVT
News
- 2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]Yahoo! Finance
- 2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why [Yahoo! Finance]Yahoo! Finance
- 2seventy bio, Inc. (NASDAQ: TSVT) had its price target raised by analysts at Citigroup Inc. from $9.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy [Yahoo! Finance]Yahoo! Finance
- 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronBusiness Wire
TSVT
Earnings
- 3/5/24 - Beat
TSVT
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- TSVT's page on the SEC website